VistaGen Therapeutics
VTGN
20 hedge funds and large institutions have $2.02M invested in VistaGen Therapeutics in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
18% more funds holding
Funds holding: 17 → 20 (+3)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.4% less ownership
Funds ownership: 0.72% → 0.32% (-0.4%)
61% less capital invested
Capital invested by funds: $5.23M → $2.02M (-$3.21M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$223K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$217K |
| 3 |
CA
Corrado Advisors
Ramsey,
New Jersey
|
+$82.3K |
| 4 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
+$28.6K |
| 5 |
CWA
Clarus Wealth Advisors
Peoria,
Arizona
|
+$18.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.44M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$926K |
| 3 |
NC
Nexthera Capital
New York
|
-$154K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$55.7K |
| 5 |
AWCI
Alpine Woods Capital Investors
Purchase,
New York
|
-$50K |
VTGN Hedge Fund Activity: Q1 2018 in Review
20 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2018, worth a combined $2.02M — down 61% from $5.23M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VTGN positions and 6 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Ibex Investors, opening a new position worth an estimated $223K. The largest seller was Sabby Management, cutting an estimated $2.44M.
- 20 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2018, up from 17 in Q4 2017.
- Funds reported $2.02M of VistaGen Therapeutics stock for Q1 2018, down 61% quarter-over-quarter.
- 9 funds opened new VistaGen Therapeutics positions in Q1 2018 and 6 closed out, a net change of +3 holders.
- The largest VistaGen Therapeutics buyer in Q1 2018 was Ibex Investors, an estimated $223K added.
- The largest VistaGen Therapeutics seller in Q1 2018 was Sabby Management, an estimated $2.44M sold.
Based on aggregated 13F filings for Q1 2018.